Search clinical trials for: CNTO 148

Total 4670 results

Janssen Pharmaceutical K.K.

Completed

Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus

Healthy | Diabetes Mellitus, Type 2

Japan
Rachel Lieberman

Terminated

Capsular Tension Rings in Intraocular Lens Rotation

Cataract | Ophthalmoplegia | Ophthalmologic Complication

United States
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

The Mass Balance Study of LP-168 in Healthy Subjects

Clinical Pharmacology

China
Vivozon, Inc.

Completed

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

Healthy Adult Male

United States
Janssen Pharmaceutical K.K.
Mitsubishi Tanabe Pharma Corporation

Completed

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

Healthy

United States
Centocor, Inc.

Withdrawn

A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma

Asthma
Centocor, Inc.
Schering-Plough

Completed

A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis

Spondylitis, Ankylosing

United States, Germany, Finland, Taiwan, Korea, Republic of, Canada, Belgium, Netherlands, France
Centocor, Inc.

Completed

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
Davidzon, Guido, M.D.

Terminated

18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

Osteosarcoma

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Healthy Male Subjects

Japan
Janssen Pharmaceutical K.K.

Withdrawn

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy | Visual Acuity

Japan
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Centocor, Inc.

Terminated

A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Iovance Biotherapeutics, Inc.

Recruiting

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Squamous Cell Carcinoma of the Head and Neck | Metastatic Melanoma | Non-small Cell Lung Cancer

United States, Spain, Canada, France, Germany, Greece, Switzerland, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Poland, Germany, Taiwan, Malaysia, Korea, Republic of, Czech Republic, Russian Federation, Hungary
GE Healthcare
National Cancer Institute (NCI)

Terminated

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

Prostate Cancer

United States
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Japan
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Centocor, Inc.

Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Completed

A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16

Healthy Volunteers and Asthma

United Kingdom, Canada, Netherlands, Germany, Denmark, Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA)

Hidradenitis Suppurativa

United States, France, Canada, Germany, Netherlands, Denmark
Centocor, Inc.

Completed

A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma

Asthma

Germany, United Kingdom, Belgium
Mayo Clinic
Blue Earth Diagnostics, Inc

Recruiting

18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain

Metastatic Intracranial Malignant Neoplasm | Recurrent Intracranial Neoplasm

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (THEIA)

Giant Cell Arteritis

United States, Canada, Belgium, Israel, Italy, Germany, France, Spain, Poland
University of Calgary

Not yet recruiting

Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism

Primary Aldosteronism

Canada
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Healthy | Systemic Lupus Erythematosus

United States, Spain, Romania, Taiwan, Belgium, Poland, Moldova, Republic of
Centocor, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis

United States, Canada, Netherlands, Belgium, Germany
Centocor, Inc.

Completed

First Study of the Safety of CNTO 888 in Patients With Solid Tumors

Cancer
Centocor, Inc.

Completed

A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers

Healthy
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC

Terminated

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

Colitis, Ulcerative

United States, Poland, Germany, France, India, Romania, Serbia, Ukraine, Israel, Canada, Netherlands, Sweden, New Zealand, Russian Federation, Australia, Belgium, Hungary, Bulgaria, Slovakia, Latvia, Lithuania, Austria
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Japan
Seoul National University Hospital
Seoul National University Bundang Hospital

Completed

Plasmalyte-148 Solution and Blood Coagulation

Blood Coagulation Disorder

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration

United States
University of Washington
Janssen Scientific Affairs, LLC

Recruiting

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
Saisei Pharma

Completed

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)

Covid19

Ukraine
Johnson & Johnson Consumer Inc. (J&JCI)

Completed

A Study to Evaluate the Efficacy of Investigational OTC Eye Drops

Ophthalmic Solutions

United States
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

Metastatic Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma in Cervical Lymph Node

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery

Glioblastoma

United States
Centocor, Inc.

Completed

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

France, United Kingdom, Netherlands, Czech Republic
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (PRELUDE)

Macular Degeneration | Geographic Atrophy | Visual Acuity

United States
Centocor, Inc.

Completed

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Lymphoma, Non-Hodgkin | Multiple Myeloma | Giant Lymph Node Hyperplasia

United States

3

Subscribe